A lean and focused diagnostic company
Immunovia AB (publ.) is a lean, focused diagnostic company seeking to revolutionize early detection of pancreatic cancer. We aim to improve outcomes for people at high risk of pancreatic cancer by detecting the disease at Stage 1 or 2 with our highly accurate blood test, PancreaSure. Immunovia plans to launch PancreaSure in the United States in the second half of 2025.
Immunovia was founded in Lund, Sweden based on protein research at Lund University. The company’s clinical lab and many of its employees are in the U.S.A., the company’s first commercial market.
Immunovia stock trades on the Nasdaq Stockholm exchange under the ticker symbol IMMNOV.
To learn more about investing in Immunovia click the button below.
Important Recent Events
Launch of IMMray PanCan-d
In Q3 2021, Immunovia launched IMMray PanCan-d, the first blood test dedicated to the early detection of pancreatic cancer. The IMMray PanCan-d test was used and adopted throughout the United States at many high-risk surveillance centers. The IMMray® PanCan-d test has since been discontinued, but the test paved the way for the next-generation test the Company is now developing.
Began development of the next-generation test
In Q3 2022, Immunovia initiated development of its next-generation test for early detection of pancreatic cancer. The Company sought to identify new, more accurate biomarkers to increase test performance. In November 2022, Immunovia entered into an agreement with the Swiss company Proteomedix AG to access their extensive experience in developing protein-based assays to detect cancer.
Jeff Borcherding promoted to CEO
To streamline operations and increase focus on the American market, Immunovia’s board of directors appointed Jeff Borcherding as CEO in April 2023. Jeff had previously led the Company’s US operations since joining Immunovia a year earlier. He immediately began a strategic review to identify changes needed to ensure the success of the Company.
Initiated a transformation of Immunovia
The company began a broad and sweeping transformation in July 2023. The transformation was intended to significantly lower costs, increase productivity, and drive speed. Immunovia discontinued the IMMray PanCan-d test to focus resources on its next-generation test. The Company also transitioned to the commercially available ELISA platform to enable faster and less expensive testing compared to the previous proprietary IMMray® platform. Finally, staffing and operating expenses were substantially reduced.
Successfully completed the discovery phase of the next-generation test
The discovery study marked a critical milestone in the development of Immunovia's next-generation test for early detection of pancreatic cancer. Over a dozen proteins were identified that can be used to detect stage I and II pancreatic ductal adenocarcinoma (PDAC) in the blood. This was the most comprehensive pancreatic cancer proteomics study to date and used the Olink platform to explore nearly 3,000 protein biomarkers. The promising biomarkers identified in the discovery study were then transitioned to the ELISA platform for further testing.
Positive results from the model development study
The next-generation test for pancreatic cancer achieved both the primary and secondary endpoints in a model development study. In the study, Immunovia's next-generation test demonstrated a specificity of 98% and a sensitivity of 75% for detecting early stages (1 and 2) of PDAC (pancreatic ductal adenocarcinoma), a highly aggressive and the most common form of pancreatic cancer. Immunovia's test was also significantly more accurate than CA19-9, the biomarker typically used for detecting pancreatic cancer.
Moved the laboratory to Research Triangle Park, North Carolina
To further streamline operations and reduce costs, Immunovia moved its lab and US headquarters to Research Triangle Park, North Carolina in May 2024. The new lab in RTP is smaller and more cost-effective than the prior lab in Marlborough, Massachusetts. The RTP market also offered a rich and cost-effective labor market, enabling Immunovia to staff the lab with talented employees at a lower cost.
Strategic partner
Immunovia is actively pursuing a strategic collaboration at the appropriate time with a large diagnostics company to expand commercial reach and accelerate market penetration.
Leadership
Immunovia’s executive team has blended scientific, clinical and commercial expertise to build the leading company in early detection of pancreatic cancer. They learned best practices at many of the world’s top life science companies and learned to move quickly and operate efficiently at high-growth early stage companies.
Jeff Borcherding
Norma Palma, PhD
Lisa Ford, PhD, HCLD
Tom King, MD, PhD
Board of Directors
Immunovia has assembled a diverse and cohesive board with expertise in multiple areas to successfully guide the company through both test development and commercialization.
Peter Høngaard Andersen, MD
Valerie Bogdan-Powers
Melissa Farina
Michael Löfman
Martin Møller
Hans Johannsson
Join our mission
Immunovia’s talented, diligent team members drive our success. We are a small, efficient, collaborative team of people committed to achieving our mission of detecting pancreatic cancer and saving lives. Interested in joining the team and making a difference for people at high risk for pancreatic cancer?
Visit our LinkedIn page to see our open roles
Job Openings
We are looking for a motivated and experienced Senior Manager / Associate Director of Biostatistics and Clinical Data Management to support our mission of early pancreatic cancer detection.
Contact us
Email:
info@immunovia.com
Visiting address:
Medicon Village
Scheelevägen 2,
Lund
Postal address:
Immunovia AB
Medicon Village
SE-223 63 Lund
Email:
info@immunovia.com
Visiting address:
800 Capitola Dr. Suite 1
Durham, NC 27713
Postal address:
Immunovia
6409 Fayetteville Rd.
Suite 120-364
Durham, NC27713
Email:
helloir@immunovia.com
Jeff Borcherding
CEO
©2025 Immunovia. All rights reserved